We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Usage Study of Statins in Primary Care in France

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00680082
First Posted: May 19, 2008
Last Update Posted: December 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
To describe the way statins are used in France in primary care, that is to determine patients profile (particularly CV risk factors), to determine the way statins are initiated by general practitioners, to evaluate aftercare and to assess patients treated by rosuvastatin

Condition
Healthy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Observational Usage Study of Statins in Primary Care in France

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 2100
Study Start Date: February 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients to whom a statin was initiated or switched between 3 and 6 months before consultation

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients recruited by a GP, community sample
Criteria

Inclusion Criteria:

  • Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00680082


  Show 25 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Francois Morand Cegedim Strategic Data - Boulogne Billancourt - France
Study Chair: Jean Dallongeville Institut Pasteur - Inserm U744 - Lille -France
  More Information

Responsible Party: Russel Esterline, AstraZeneca
ClinicalTrials.gov Identifier: NCT00680082     History of Changes
Other Study ID Numbers: NIS-CFR-CRE-2007/2
First Submitted: May 15, 2008
First Posted: May 19, 2008
Last Update Posted: December 2, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
statins
rosuvastatin
cross sectional study
France
CV risk factors

Additional relevant MeSH terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents